Characterizing biomolecular markers in bone metastasis
Biomolecular Markers of Bone Metastasis
This study is trying to find specific markers in the bones of patients with certain cancers to see if they can help predict how the cancer will spread and the risk of fractures.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 160 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna Academic / other |
| Locations | 1 site (Bologna, Bologna) |
| Trial ID | NCT06806462 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to identify the biomolecular profile of bone metastases in patients with breast, lung, renal, gastroenteric, or prostate carcinomas. By analyzing samples from both primary tumors and bone metastases, the study seeks to uncover biomarkers that may predict the progression of bone metastasis and the risk of pathological fractures. The approach involves multidisciplinary management and unsupervised analysis of transcriptomes to highlight significant molecular changes associated with metastasis. The findings could lead to improved understanding and management of bone metastasis in affected patients.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with breast, lung, renal, gastroenteric, or prostate carcinomas that have metastasized to bone.
Not a fit: Patients without bone metastases or those with other types of cancer not specified in the inclusion criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide critical insights into predicting bone metastasis progression, potentially leading to better-targeted therapies.
How similar studies have performed: While the approach of identifying biomolecular markers in metastasis is being explored in various studies, this specific focus on bone metastasis and its predictive biomarkers is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \>= 18 years * Patients with breast or lung or renal or gastroenteric tract or prostate with bone metastases * Patients who knowingly express willingness to participate in the study after signing the written informed consent Exclusion Criteria: * None
Where this trial is running
Bologna, Bologna
- IRCCS Azienda Ospedaliero-Universitaria di Bologna — Bologna, Bologna, Italy (Recruiting)
Study contacts
- Principal investigator: Andrea Sambri, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Study coordinator: Andrea Sambri, MD
- Email: andrea.sambri@aosp.bo.it
- Phone: 0512142680
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.